dm+d
68887009
Articles
Using folic acid with methotrexate in rheumatoid arthritis
20 February 2023
Folic acid is used to reduce methotrexate associated adverse effects in people with rheumatoid arthritis. This page guides appropriate dosing.Methotrexate products: information for supporting intrathecal risk assessment
11 August 2022
Methotrexate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administrationAdvising on missed or delayed doses of medicines
15 October 2021
Guidance to advise people who occasionally forget or are late in taking a dose of their medicine(s).Methotrexate monitoring
5 July 2021
What injections can be given orally or via enteral feeding tubes?
6 November 2020
This updated Medicines Q&A is a quick reference summary to different types of enteral feeding tubes, in relation to medication issues. Not all enteral feeding…Medicine Compliance Aid Stability
Maxtrex
Pfizer Ltd
Pfizer Ltd
Maxtrex
Tablets 2.5mg, 10mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are cytotoxic.
19 August 2022
generic
Hospira UK
Hospira UK
generic
Tablets 10mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are cytotoxic.
20 December 2022
generic
Orion Pharma (UK) Ltd
Orion Pharma (UK) Ltd
generic
Tablets 2.5mg, 10mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are cytotoxic.
20 December 2022
generic
Sandoz Ltd
Sandoz Ltd
generic
Tablets 2.5mg, 10mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are cytotoxic.
20 December 2022
Lactation Safety Information
As antineoplastic
As antineoplastic
Limited published evidence indicates small amounts in breast milk
If used as monotherapy, monitor infant’s blood count and do not resume breastfeeding until at least 4 days after a dose – longer with high doses
Discontinue breastfeeding if used in combination with other antineoplastics
17 September 2018
For rheumatoid arthritis
For rheumatoid arthritis
See summary
Limited published evidence indicates small amounts in breast milk after weekly administration
Monitor infant’s blood count and do not resume breastfeeding until at least 24 hours after a weekly dose not exceeding 25mg
19 September 2019
For psoriasis
For psoriasis
Topical psoriasis preparation / corticosteroid if appropriate
Limited published evidence indicates small amounts in breast milk after weekly administration
Monitor infant’s blood count and do not resume breastfeeding until at least 24 hours after a weekly dose not exceeding 25mg
16 September 2019
For inflammatory bowel disease
For inflammatory bowel disease
See summary
Limited published evidence indicates small amounts in breast milk after weekly administration
Monitor infant’s blood count and do not resume breastfeeding until at least 24 hours after a weekly dose not exceeding 25mg
16 September 2019